Comparative between Pfizer and SinoPharm Vaccinated Production Antibody

Abstract

Vaccines against SARS-CoV-2 stimulate immune responses through a variety of methods, This research aims to examine the values of particular antibodies (IgG) in people who have been vaccinated against the disease in Pfizer-BioNTech SARS-CoV-2  or the Other SARS-CoV-2  vaccine or the SinoPharm-BBIBP-CorV vaccine, Participants in this future-looking observational studies iraqi adults vaccination received in two separate doses, 3 weeks apart, vaccination with any of the two vaccinations described above, After a delay of 8 weeks after the delivery of the second dosage, titers were obtained, overall, 45 Included individuals, of which 15 the medication was given to Pfizer-BioNTech vaccine, while 15 the medication was given to SinoPharm vaccine, 15 healthy group non-vaccinated, Remarkably, 15 (100 %) Among those vaccinated with the Pfizer-BioNTech vaccine Nucleocapsid IgG titers that Mean ± SD (49.451 ± 10.166), but Neutralizing IgG titer negative 15 (100 %) that Mean ± SD (0.241 ± 0.025) compared with control group that Mean ± SD (0.290 ± 0.046) at a probability level of (P≤0.01), while 15 (100 %) of SinoPharm recipients had positive Nucleocapsid IgG titers that Mean ± SD (99.141 ± 33.132), Neutralizing IgG titer Positive 15 (100 %) that Mean ± SD (0.972 ±0.308) compared with control group that Mean ± SD (0.290±0.046) at a probability level of (P≤0.01).